DOTAP and DP7-C liposomes |
|
Vaxjo ID |
229 |
|
Vaccine Adjuvant Name |
DOTAP and DP7-C liposomes |
|
Adjuvant VO ID |
VO_0005716
|
|
Description |
DP7-C-modified DOTAP liposomes function as a dual-use system—mRNA delivery vehicle and immune adjuvant, improving antigen presentation and immune responses |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
As a carrier of mRNA, DP7-C-modified DOTAP liposomes (DOTAP/DP7-C) could transfer mRNA efficiently into different type of DCs in vitro. |
|
Structure |
Cationic liposomes (~100 nm) composed of DOTAP, cholesterol, and surface-bound DP7-C peptide |
|
Appearance |
Well-dispersed nanoparticles; visualized by TEM as spherical vesicles |
|
Storage |
Stable at 4°C for up to 6 months |
|
Preparation |
DOTAP and cholesterol co-dissolved in chloroform → dried into lipid film → rehydrated with DP7-C in water (thin-film dispersion method) |
|
Dosage |
mRNA: 10 µg Liposomes: 20 µg per dose (subcutaneous injection in mice) |
|
Function |
As an immunoadjuvant, DOTAP/DP7-C liposomes were shown to be more efficacious in stimulating DC maturation, CD103+ DC (contributing to antigen presentation) production and proinflammatory cytokine secretion than DOTAP liposomes both in vitro and in vivo. In animal studies, the subcutaneous administration of DOTAP/DP7-C/LL2 neoantigen-encoding mRNA complexes significantly inhibited the growth of LL2 in situ and the growth of subcutaneous tumors and stimulated the production of antigen-specific lymphocyte reactions, which were superior to the DOTAP/LL2 neoantigen-encoding mRNA complex group. In conclusion, DOTAP/DP7-C liposomes may serve as a potential universal mRNA delivery system, providing a simple method to increase the efficiency of intracellular mRNA delivery and the immunostimulatory activity of DCs |
|
Safety |
Low toxicity in vitro and in vivo; higher IC50 (>100 µg/mL) compared to Lipo2000 and PEI25K |
| References |
Zhang et al., 2020: Zhang R, Tang L, Tian Y, Ji X, Hu Q, Zhou B, Ding Z, Xu H, Yang L. DP7-C-modified liposomes enhance immune responses and the antitumor effect of a neoantigen-based mRNA vaccine. Journal of controlled release : official journal of the Controlled Release Society. 2020; 328; 210-221. [PubMed: 32860927].
|
